{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:16:55Z","timestamp":1793459815806,"version":"4.5.0"},"reference-count":37,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2023,1,25]]},"DOI":"10.1253\/circj.cj-22-0314","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T22:22:19Z","timestamp":1665094939000},"page":"336-344","source":"Crossref","is-referenced-by-count":28,"title":["Relationships Among Heart Rate, \u03b2-Blocker Dosage, and Prognosis in Patients With Coronary Artery Disease in a Real-World Database Using a Multimodal Data Acquisition System"],"prefix":"10.1253","volume":"87","author":[{"given":"Yusuke","family":"Oba","sequence":"first","affiliation":[{"name":"Jichi Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Kabutoya","sequence":"additional","affiliation":[{"name":"Jichi Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Kohro","sequence":"additional","affiliation":[{"name":"Jichi Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Imai","sequence":"additional","affiliation":[{"name":"Jichi Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Kario","sequence":"additional","affiliation":[{"name":"Jichi Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisahiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Precision Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nochioka","sequence":"additional","affiliation":[{"name":"Tohoku University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Tohoku University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Fujita","sequence":"additional","affiliation":[{"name":"Jichi Medical University Saitama Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Mizuno","sequence":"additional","affiliation":[{"name":"The University of Tokyo"},{"name":"Development Bank of Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arihiro","family":"Kiyosue","sequence":"additional","affiliation":[{"name":"The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Iwai","sequence":"additional","affiliation":[{"name":"National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Nakano","sequence":"additional","affiliation":[{"name":"Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Matoba","sequence":"additional","affiliation":[{"name":"Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryozo","family":"Nagai","sequence":"additional","affiliation":[{"name":"Jichi Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. <i>Arch Intern Med<\/i> 2002; 162: 2313\u20132321.","DOI":"10.1001\/archinte.162.20.2313"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fujiura Y, Adachi H, Tsuruta M, Jacobs DR Jr, Hirai Y, Imaizumi T. Heart rate and mortality in a Japanese general population: An 18-year follow-up study. <i>J Clin Epidemiol<\/i> 2001; 54: 495\u2013500.","DOI":"10.1016\/S0895-4356(00)00323-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Elliott P, et al. Resting heart rate and cause-specific death in a 16.5-year cohort study of the Japanese general population. <i>Am Heart J<\/i> 2004; 147: 1024\u20131032.","DOI":"10.1016\/j.ahj.2003.12.020"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Jouven X, Empana JP, Escolano S, Buyck JF, Tafflet M, Desnos M, et al. Relation of heart rate at rest and long-term (&gt;20 years) death rate in initially healthy middle-aged men. <i>Am J Cardiol<\/i> 2009; 103: 279\u2013283.","DOI":"10.1016\/j.amjcard.2008.08.071"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hozawa A, Ohkubo T, Kikuya M, Ugajin T, Yamaguchi J, Asayama K, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: The Ohasama study. <i>Am J Hypertens<\/i> 2004; 17: 1005\u20131010.","DOI":"10.1016\/S0895-7061(04)00897-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tverdal A, Hjellvik V, Selmer R. Heart rate and mortality from cardiovascular causes: A 12 year follow-up study of 379,843 men and women aged 40\u201345 years. <i>Eur Heart J<\/i> 2008; 29: 2772\u20132781.","DOI":"10.1093\/eurheartj\/ehn435"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial. <i>Lancet<\/i> 2008; 372: 817\u2013821.","DOI":"10.1016\/S0140-6736(08)61171-X"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. <i>Eur Heart J<\/i> 2005; 26: 967\u2013974.","DOI":"10.1093\/eurheartj\/ehi190"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kato N, Kinugawa K, Imamura T, Muraoka H, Minatsuki S, Inaba T, et al. Trend of clinical outcome and surrogate markers during titration of \u03b2-blocker in heart failure patients with reduced ejection fraction: Relevance of achieved heart rate and \u03b2-blocker dose. <i>Circ J<\/i> 2013; 77: 1001\u20131008.","DOI":"10.1253\/circj.CJ-12-1241"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fiuzat M, Wojdyla D, Kitzman D, Fleg J, Keteyian SJ, Kraus WE, et al. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: Results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. <i>J Am Coll Cardiol<\/i> 2012; 60: 208\u2013215.","DOI":"10.1016\/j.jacc.2012.03.023"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O\u2019Connor CM. Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: Results from the HF-ACTION trial. <i>JACC Heart Fail<\/i> 2016; 4: 109\u2013115.","DOI":"10.1016\/j.jchf.2015.09.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Okamoto H, Hori M, Matsuzaki M, Tsutsui H, Yamazaki T, Nagai R, et al. Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. <i>Int J Cardiol<\/i> 2013; 164: 238\u2013244.","DOI":"10.1016\/j.ijcard.2012.11.051"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: Beta-blocker dose, heart rate reduction, and death in patients with heart failure. <i>Ann Intern Med<\/i> 2009; 150: 784\u2013794.","DOI":"10.7326\/0003-4819-150-11-200906020-00006"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kjekshus J. Is there a heart rate paradox: Demystification of the myths? <i>J Intern Med<\/i> 2009; 266: 242\u2013247.","DOI":"10.1111\/j.1365-2796.2009.02143.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Porapakkham P, Porapakkham P, Krum H. Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure? <i>Cardiovasc Ther<\/i> 2010; 28: 93\u2013100.","DOI":"10.1111\/j.1755-5922.2010.00136.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: Systematic review and meta regression analysis. <i>BMJ<\/i> 1999; 318: 1730\u20131737.","DOI":"10.1136\/bmj.318.7200.1730"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, et al. Clinical outcomes with \u03b2-blockers for myocardial infarction: A meta-analysis of randomized trials. <i>Am J Med<\/i> 2014; 127: 939\u2013953.","DOI":"10.1016\/j.amjmed.2014.05.032"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, et al. Meta-analysis of relation between oral \u03b2-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. <i>Am J Cardiol<\/i> 2015; 115: 1529\u20131538.","DOI":"10.1016\/j.amjcard.2015.02.057"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. <i>Lancet<\/i> 2001; 357: 1385\u20131390.","DOI":"10.1016\/S0140-6736(00)04560-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Watanabe H, Ozasa N, Morimoto T, Shiomi H, Bingyuan B, Suwa S, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. <i>PLoS One<\/i> 2018; 13: e0199347.","DOI":"10.1371\/journal.pone.0199347"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Matoba T, Kohro T, Fujita H, Nakayama M, Kiyosue A, Miyamoto Y, et al. Architecture of the Japan Ischemic Heart Disease Multimodal Prospective Data Acquisition for Precision Treatment (J-IMPACT) System. <i>Int Heart J<\/i> 2019; 60: 264\u2013270.","DOI":"10.1536\/ihj.18-113"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Nakayama M, Takehana K, Kohro T, Matoba T, Tsutsui H, Nagai R. Standard export data format for extension storage of standardized structured medical information exchange. <i>Circ Rep<\/i> 2020; 2: 587\u2013616.","DOI":"10.1253\/circrep.CR-20-0077"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kimura M, Nakayasu K, Ohshima Y, Fujita N, Nakashima N, Jozaki H, et al. SS-MIX: A ministry project to promote standardized healthcare information exchange. <i>Methods Inf Med<\/i> 2011; 50: 131\u2013139.","DOI":"10.3414\/ME10-01-0015"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al; Japanese Circulation Society Joint Working Group. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. <i>Circ J<\/i> 2019; 83: 1085\u20131196.","DOI":"10.1253\/circj.CJ-19-0133"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Okada S, Iwahana T, Kobayashi Y. Is high heart rate always harmful to heart failure patients? <i>Circ J<\/i> 2020; 84: 1673\u20131674.","DOI":"10.1253\/circj.CJ-20-0198"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Tsutsui H, Ide T, Kawasaki Y. Is high heart rate always harmful to heart failure patients?: Reply. <i>Circ J<\/i> 2020; 84: 1674\u20131675.","DOI":"10.1253\/circj.CJ-20-0590"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. <i>Circulation<\/i> 2004; 109: 1674\u20131679.","DOI":"10.1161\/01.CIR.0000118464.48959.1C"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Campana C, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. <i>Eur J Heart Fail<\/i> 2008; 10: 550\u2013555.","DOI":"10.1016\/j.ejheart.2008.04.005"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Milliez P, Messaoudi S, Nehme J, Rodriguez C, Samuel JL, Delcayre C. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. <i>Am J Physiol Heart Circ Physiol<\/i> 2009; 296: H435\u2013H441.","DOI":"10.1152\/ajpheart.00591.2008"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Reil JC, Tardif JC, Ford I, Lloyd SM, O\u2019Meara E, Komajda M, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. <i>J Am Coll Cardiol<\/i> 2013; 62: 1977\u20131985.","DOI":"10.1016\/j.jacc.2013.07.027"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Custodis F, Schirmer SH, Baumh\u00e4kel M, Heusch G, B\u00f6hm M, Laufs U. Vascular pathophysiology in response to increased heart rate. <i>J Am Coll Cardiol<\/i> 2010; 56: 1973\u20131983.","DOI":"10.1016\/j.jacc.2010.09.014"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. <i>Lancet<\/i> 2008; 372: 807\u2013816.","DOI":"10.1016\/S0140-6736(08)61170-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Swedberg K, Komajda M, B\u00f6hm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. <i>Lancet<\/i> 2010; 376: 875\u2013885.","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Tardif JC, O\u2019Meara E, Komajda M, B\u00f6hm M, Borer JS, Ford I, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy. <i>Eur Heart J<\/i> 2011; 32: 2507\u20132515.","DOI":"10.1093\/eurheartj\/ehr311"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Nakamura M, Yaku H, Ako J, Arai H, Asai T, Chikamori T, et al. JCS\/JSCVS 2018 guideline on revascularization of stable coronary artery disease. <i>Circ J<\/i> 2022; 86: 477\u2013588.","DOI":"10.1253\/circj.CJ-20-1282"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Tsutsui H, Momomura SI, Masuyama T, Saito Y, Komuro I, Murohara T, et al. Tolerability, efficacy, and safety of bisoprolol vs. carvedilol in Japanese patients with heart failure and reduced ejection fraction: The CIBIS-J Trial. <i>Circ J<\/i> 2019; 83: 1269\u20131277.","DOI":"10.1253\/circj.CJ-18-1199"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>Eur Heart J<\/i> 2021; 42: 1289\u20131367.","DOI":"10.1093\/eurheartj\/ehab088"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/87\/2\/87_CJ-22-0314\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:41:11Z","timestamp":1715316071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/87\/2\/87_CJ-22-0314\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-22-0314","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"article-number":"CJ-22-0314"}}